Geographic Atrophy Treatment Pipeline Analysis 2025

DelveInsight's "Geographic Atrophy Pipeline Analysis, 2025" delivers extensive intelligence on over 23 pharmaceutical firms and more than 25 investigational medications within the Geographic Atrophy development arena. The analysis encompasses profiles of the pipeline therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.

Interested in recent developments within the Geographic Atrophy Pipeline? Discover the emerging treatments and clinical studies generating attention @ Geographic Atrophy Pipeline Outlook Report

Primary Highlights from the Geographic Atrophy Pipeline Analysis

• On November 10, 2025, Astellas Pharma Inc. revealed that an investigation is for individuals in Japan of 40 years of age or older, who have geographic atrophy. The primary objective of this investigation is to collect information about the safety profile of ASP3021 and how well individuals tolerate treatment with ASP3021. During the investigation, individuals will receive monthly injections of ASP3021 for 12 months. ASP3021 is administered by injection into the affected eye. This procedure is called an intravitreal injection.

• On November 7, 2025, Janssen Research & Development LLC initiated an investigation to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

• DelveInsight's Geographic Atrophy Pipeline analysis reveals a dynamic field featuring more than 23 engaged entities advancing over 25 investigational treatments for Geographic Atrophy management.

• Major Geographic Atrophy pharmaceutical firms include Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, among additional organizations.

• Notable Geographic Atrophy investigational medications include OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007, among others.

Curious about which pharmaceutical companies are pioneering advancement in Geographic Atrophy treatment? Explore comprehensive pipeline intelligence @ Geographic Atrophy Clinical Trials Assessment

The Geographic Atrophy Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Geographic Atrophy.

Geographic Atrophy Background

Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The condition is distinguished by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It typically starts in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases.

Geographic Atrophy Investigational Drug Profiles

IONIS-FB-LRx: Ionis Pharmaceuticals

IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine engineered to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.

Zimura: IVERIC bio

Zimura (avacincaptad pegol) is an investigational drug product engineered to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration.

Monitoring active Geographic Atrophy Clinical investigations? This announcement is essential reading. Access the latest advances @ Geographic Atrophy Treatment Drugs

The Geographic Atrophy Pipeline Analysis Offers Intelligence On:

• The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Geographic Atrophy management, including cumulative therapies created by each organization for this indication.

• It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Geographic Atrophy Treatment.

• Geographic Atrophy pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives.

• Geographic Atrophy investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification.

• Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Geographic Atrophy market.

Geographic Atrophy Pharmaceutical Firms

Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, among additional organizations.

The Geographic Atrophy Pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

Geographic Atrophy products are classified under various molecular categories including:

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

From investigational drug candidates to competitive intelligence, the Geographic Atrophy Pipeline Analysis encompasses comprehensive insights - review it today @ Geographic Atrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Geographic Atrophy Pipeline Analysis

• Coverage: Global

• Geographic Atrophy Pharmaceutical Firms: Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, among additional organizations.

• Geographic Atrophy Investigational Treatments: OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007, among others.

• Geographic Atrophy Therapeutic Evaluation by Product Category: Monotherapy, Combination, Mono/Combination

• Geographic Atrophy Therapeutic Evaluation by Clinical Phases: Discovery, Preclinical, Phase I, Phase II, Phase III

Stay informed in Healthcare Research - uncover future directions for the Geographic Atrophy Treatment landscape through this comprehensive analysis @ Geographic Atrophy Emerging Drugs and Major Players

Table of Contents

1. Introduction

2. Executive Summary

3. Geographic Atrophy: Background

4. Pipeline Therapeutics

5. Therapeutic Evaluation

6. Geographic Atrophy - DelveInsight's Analytical Perspective

7. Late Phase Products (Phase III)

8. Zimura: IVERIC bio

9. Drug profiles in the comprehensive report.....

10. Mid Phase Products (Phase II)

11. IONIS-FB-LRx: Ionis Pharmaceuticals

12. Drug profiles in the comprehensive report.....

13. Inactive Products

14. Geographic Atrophy Key Pharmaceutical Firms

15. Geographic Atrophy Key Products

16. Geographic Atrophy- Unaddressed Medical Needs

17. Geographic Atrophy- Market Drivers and Obstacles

18. Geographic Atrophy- Future Outlook and Conclusion

19. Geographic Atrophy Analyst Perspectives

20. Geographic Atrophy Key Pharmaceutical Firms

21. Appendix

About Us

DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com